AGP Picks
View all

Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on May 22, 2026

Dr. Sobti of Texas Eye and Cataract performs World's First Microsurgical Ribbon Cutting
CollaboratingPhysician.com Expands as Physicians Seek Part-Time Oversight Roles As Private Practice Ownerships Decline
All Aboard ABA Opens in Sugar Land, Offering Houston-Area Families a Faster Path to Autism Therapy
Provider Training Matters for Cosmetic Laser Procedures
Face Forward Houston Opens New Location in The Heights: Redefining Facial Plastic Surgery and Deep Plane Rejuvenation
PitPat Launches 'Run for the Future' Charity Challenge Turning Every Step Into a Brighter Future for the Next Generation
Organifi Parasite Cleanse Kit: The Most Effective Herbal Parasite Binding Detox Supplements on the Market
Slim Tide Under Investigation: Critical Research Details Ingredients' Effectiveness for Metabolic & Digestive Support
Calidi Biotherapeutics Provides Required NYSE American Disclosure
GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
SCYNEXIS Announces One-for-Eight Reverse Stock Split
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
XTL Announces Receipt of Staff Delist Determination from Nasdaq
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH

Share this page:

Sign up for:

Healthcare Wire Texas

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.